Sirnaomics Bets On RNAi In China With First IND Approval
Executive Summary
Alan Y Lu, Executive VP of RNAi developer Sirnaomics, talks to Scrip’s Brian Yang about the US-China hybrid's plan to develop anti-fibrosis therapies in both markets.
Topics
- Subjects
- Platform Technologies
- StartUps and SMEs
- Research & Development
- Regions
- Asia Pacific
- Industries
- BioPharmaceutical
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC099068
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.
All fields are required.
SC099068
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.